Blood Stopper (Ankaferd)

ApprovedSmall molecule

AAnkara Ataturk Sanatorium Training and Research Hospital

Blood Stopper (Ankaferd) is one of 11 small molecule programs targeting Epistaxis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

EpistaxisActive, not recruiting

EpistaxisApproved

Active, not recruiting

Competition

Competitive Landscape

14 competitors in Epistaxis

#DrugCompanyPhaseTrials

Cyklokapron

AAmring

Approved

5 2

Avastin

BBio-Thera Solutions

Approved

1 3

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 4

Bactroban

PPadagis LLC

Approved

—5

Adrenaline

SSamson Clinical Operations Pty Ltd

Phase 2

1 6

Rhofade

KKenvue Brands

Phase 2

1 7

Blood Stopper (Ankaferd)

AAnkara Ataturk Sanatorium Training and Research Hospital

Approved

1 8

Silver Nitrate

MMansoura University Hospital

Preclinical

1 9

Floseal

UUnity Health Toronto

Preclinical

2 10

Trichloroacetic Acid

IIndonesia University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Epistaxis1 trial

Tranexamic Acid Versus Blood Stopper Treatments in Epistaxis Management

Not yet recruiting·—·Phase 4·NCT06490653·186 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Blood Stopper (Ankaferd). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Blood Stopper (Ankaferd) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Blood Stopper (Ankaferd). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ankara Ataturk Sanatorium Training and Research Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: AAnkara Ataturk Sanatorium Training and Research Hospital

Blood Stopper (Ankaferd)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Epistaxis1 trial

References

Drug Info

Quick Facts

Related News